australasian society of clinical immunology and allergy

23 January 2025

Chair, Pharmaceutical Benefits Advisory Committee (PBAC)
Department of Health and Ageing
GPO Box 9848 Canberra ACT 2601
Email: pbac@health.gov.au

Dear PBAC Chair,

Re: Amendment to PBS listing of Remsima® SC (infliximab)

On behalf of the Australasian Society of Clinical Immunology and Allergy (ASCIA) we are writing in support of the request by Celltrion Healthcare Australia Pty Ltd to amend the Pharmaceutical Benefits Scheme (PBS) listing of Remsima® SC (infliximab), as outlined in the table below, for review at the March 2025 PBAC meeting.

INFLIXIMAB Solution for injection 120 mg in 1 mL pre-filled pen Solution for injection 120 mg in 1 mL pre-filled syringe Remsima® SC CELLTRION HEALTHCARE AUSTRALIA PTY LTD (Change to existing listing)	Severe active rheumatoid arthritis Ankylosing spondylitis Severe psoriatic arthritis Severe chronic plaque psoriasis Severe Crohn disease, Complex refractory fistulising Crohn Disease Moderate to severe ulcerative colitis	To request an amendment to the restriction level from Authority Required (Telephone/Online) to Authority Required (STREAMLINED) for the continuing treatment of the currently listed indications of Remsima® SC.

The ASCIA membership includes clinical immunologists with expertise in managing rheumatoid arthritis and other autoimmune conditions.

ASCIA supports the ARA Rheumatoid Arthritis Clinical Care Standard which states that:

- Early diagnosis and treatment lead to better long-term clinical outcomes and a better quality of life for people with rheumatoid arthritis.
- Treatment with biological disease modifying antirheumatic drugs (biological DMARDs) such as Infliximab should be started as soon as rheumatoid arthritis is diagnosed.

Therefore, ASCIA supports streamlining of the PBS listing for continuing treatment with Remsima® SC (infliximab), to facilitate early treatment of severe active rheumatoid arthritis and other relevant autoimmune conditions with biological DMARDs.

Yours sincerely,

Dr Michael O'Sullivan
ASCIA President

Jill Smith
ASCIA CEO

Correspondence: Email jill@allergy.org.au